share_log

Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma Developed In Collaboration With Moderna

Benzinga ·  Nov 8, 2024 20:37

The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 ("GPC3"), expressing cancer cells.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment